Standout Papers

Safety, tolerability and efficacy of up-titration of guideline-directed ... 2020 2026 2022 2024392
  1. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial (2022)
    Alexandre Mebazaa, Beth A. Davison et al. The Lancet
  2. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials (2020)
    Beth A. Davison, Stephen A. Harrison et al. Journal of Hepatology

Immediate Impact

4 by Nobel laureates 23 from Science/Nature 65 standout
Sub-graph 1 of 23

Citing Papers

Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis
2025 Standout
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
2024 Standout

Works of Christopher Edwards being referenced

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
2020 Standout
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
2019

Author Peers

Author Last Decade Papers Cites
Christopher Edwards 1461 440 623 549 66 2.7k
Wolfgang Speiser 1064 541 398 420 90 3.5k
Annette Oeser 744 300 519 190 58 3.4k
Hüseyin Uyarel 1596 599 707 392 157 3.3k
Antonio Muscari 679 390 666 271 88 2.7k
Wayne Tymchak 1509 553 269 767 65 2.4k
Walter Markiewicz 1801 808 792 798 92 3.7k
Rong Tang 1358 328 279 452 37 2.3k
Celia M. Oakley 3280 950 391 928 83 4.3k
Gianfranco Gensini 1169 505 431 366 110 2.7k
Pierre Fesler 1188 478 263 1045 85 2.5k

All Works

Loading papers...

Rankless by CCL
2026